BDX · Becton, Dickinson and Company
$155.922026-07-21Sector: Healthcare; Industry: Medical - Instruments & Supplies; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$97
-37.6% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($86 · $222) Analysts Range ($159 · $204) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q2 | $19.4B | — | 12.3% | 16.1% | $2.0B | $1.8B | $3.8B | 5.6% | — | 4.5% | $44.1B | $5.29 | — |
| 2025.Q1 | $20.2B | 4.2% | 13.4% | 11.6% | $2.4B | −$3.4B | −$1.0B | 6.2% | — | 5.3% | $46.7B | $6.08 | — |
| 2025.Q2 | $20.2B | 0.0% | 13.4% | 11.0% | $2.4B | −$3.5B | −$1.1B | 5.9% | — | 5.1% | $47.3B | $6.08 | — |
| 2026.Q1 | $21.8B | 8.2% | 13.3% | 14.8% | $2.5B | $581MM | $3.1B | 5.6% | — | 5.2% | $47.5B | $5.98 | — |
| 2026.Q2 | $21.4B | -2.2% | 12.0% | 18.8% | $2.1B | $1.6B | $3.7B | 5.7% | — | 4.5% | $44.3B | $4.06 | 17.1 |
| italics below = DCF projection · 10yr Rev CAGR: 2.4% |
| 2027.Q2 | $19.4B | +-9.1% | 13.3% | 18.9% | $2.1B | $0MM | $2.1B | 7.3% | $1.9B | 4.7% | $44.3B | $6.61 | 23.6 |
| 2028.Q2 | $20.0B | +2.9% | 13.8% | 19.0% | $2.2B | −$194MM | $2.0B | 7.4% | $1.8B | 5.0% | $44.5B | $7.08 | 22.0 |
| 2029.Q2 | $20.7B | +3.6% | 13.9% | 19.2% | $2.3B | −$268MM | $2.1B | 7.6% | $1.7B | 5.2% | $44.8B | $7.37 | 21.2 |
| 2030.Q2 | $21.4B | +3.6% | 14.4% | 19.3% | $2.5B | −$317MM | $2.2B | 7.7% | $1.6B | 5.6% | $45.1B | $7.90 | 19.7 |
| 2031.Q2 | $22.2B | +3.7% | 14.4% | 19.4% | $2.6B | −$383MM | $2.2B | 7.8% | $1.5B | 5.7% | $45.5B | $8.18 | 19.1 |
|
| Term. Yr+ | $28.1B | 4.1% | 20.0% | 20.0% | $4.5B | −$2.1B | $2.4B | 8.6% | $24.5B | 8.6% | — | — | — |
Active scenario IV: $97 (-37.6% vs market)